Serious adverse events WMD of · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
Antibiotics showed no clear difference in serious adverse events WMD of compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · postmenopausal women with a higher risk for fracturesa
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.9 [0.52, 1.54]
Studies not reported
Moderate
Serious adverse events · people with inhibitors
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · people without inhibitors
Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · people without inhibitors
Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · people without inhibitors
Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly showed no clear difference in serious adverse events compared with emicizumab 3.0 mg/kg every 2 weeks (moderate certainty).
1 finding from 1 review
Serious adverse events · people with inhibitors
Summary of findings table ‐ Emicizumab prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · children aged 5 to 11 years
1 finding from 1 review
Serious adverse events · children aged 5 to 11 years
1 finding from 1 review
Serious adverse events · children aged 5 to 11 years
1 finding from 1 review
Serious adverse events · children aged 12 to 18 years
1 finding from 1 review
Serious adverse events · children aged 12 to 18 years
1 finding from 1 review
Serious adverse events · children aged 12 to 18 years
1 finding from 1 review
Serious adverse events · people who smoke
Bupropion showed no clear difference in serious adverse events compared with placebo/no pharmacological treatment (moderate certainty).
1 finding from 1 review
Serious adverse events · people who smoke
Bupropion plus nicotine replacement therapy (NRT) showed no clear difference in serious adverse events compared with NRT alone (low certainty).
1 finding from 1 review
Serious adverse events · people who smoke
Bupropion plus varenicline showed no clear difference in serious adverse events compared with varenicline alone (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · people undergoing pancreaticoduodenectomy
1 finding from 1 review
Intervention not reported
Serious adverse events · people undergoing distal pancreatectomy
1 finding from 1 review
Serious adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 1 [0.94, 1.07]
Studies not reported
Moderate